Insulin has both direct and indirect effects on the liver; in particular, insulin indirectly reduces the transport of fatty acid to the liver by inhibiting the lipolysis of white fat and reducing the hepatic content of acetyl-CoA, an allosteric activator of pyruvate carboxylase, thus affecting the progression of NAFLD. Here, INS is linked to metabolic dysfunction-associated steatotic liver disease.